For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Degarelix
Illustration for Degarelix

THE PEPSRADAR ENCYCLOPEDIA

Degarelix

Prostate-cancer hormone therapy and cardiovascular outcomes

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Degarelix · KEY FACTS

Content updated · how dates work

Saved peptides

Half-life source: FDA label (FIRMAGON) on DailyMed ↗

What is Degarelix?

Degarelix is a GnRH antagonist used in prostate-cancer hormone therapy. PRONOUNCE examined cardiovascular events against leuprolide but ended before its planned enrollment.

Biological role or research focus

Prostate-cancer hormone therapy and cardiovascular outcomes.

Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.

Role reference: Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. · 2021 ↗

Class / identity
GnRH receptor antagonist
Research focus
Prostate-cancer hormone therapy and cardiovascular outcomes
Featured evidence
Human randomized trial
Source check
October 4, 2026

Source: Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. · 2021 ↗

Quick answers

Is Degarelix FDA approved?
Yes. Firmagon (NDA 022201, approved December 2008) for advanced prostate cancer. Source ↗
Is Degarelix safe?
Approved hormone-blocking drug for advanced prostate cancer; injection-site reactions and hot flashes are common, with heart rhythm (QT) and allergy risks. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Degarelix banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
PRONOUNCE (2021)Human randomized trial545 patients with prostate cancer and atherosclerotic cardiovascular disease; planned enrollment was 900.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2021

PRONOUNCE

Did cardiovascular events differ versus leuprolide?

Population / model
545 patients with prostate cancer and atherosclerotic cardiovascular disease; planned enrollment was 900.
Study design
Randomized open-label comparison with leuprolide over 12 months; adjudicated cardiovascular endpoints; stopped early.
Main finding
Major cardiovascular events occurred in 5.5% versus 4.1%: hazard ratio 1.28 (95% CI 0.59–2.79; P=0.53).
Limits & context
Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.

Source: Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. · 2021 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

65 registered studies name Degarelix as an intervention among the 100 most recently updated of 170 search results; 25 are recruiting or under way, 1 has not started recruiting yet, 28 completed and 11 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211 · ECOG-ACRIN Cancer Research Group
RecruitingPhase 32020-10-08804
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT04787744 · VA Office of Research and Development
Active, not recruitingPhase 2 / Phase 32021-07-01378
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
NCT06066437 · M.D. Anderson Cancer Center
RecruitingPhase 1 / Phase 22024-03-296
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
NCT05873192 · M.D. Anderson Cancer Center
RecruitingPhase 22025-06-0330
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
NCT03689699 · Mark Stein
CompletedPhase 1 / Phase 22018-10-1159
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
NCT05617885 · Praful Ravi, MB BCHir, MRCP
TerminatedPhase 12023-08-099
Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer
NCT05917860 · Turku University Hospital
Active, not recruitingPhase 12023-07-1815
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025 · SWOG Cancer Research Network
RecruitingPhase 32018-09-241273

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 65 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. ↗
BJU international · 2008 Dec · Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial

ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer. ↗
European urology · 2023 Jun · Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't

Degarelix. ↗
· 2012 · Review

Degarelix. ↗
Drugs · 2009 Oct 1 · Journal Article

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Approved hormone-blocking drug for advanced prostate cancer; injection-site reactions and hot flashes are common, with heart rhythm (QT) and allergy risks.

Human safety data: FDA label

Safety comes from FDA-approved labeling (Firmagon) based mainly on a one-year randomized trial against leuprolide in men with prostate cancer, plus postmarketing reports. No formal drug interaction studies were done.

Take extra care with: Heart or blood pressure problemsPregnancy or breastfeeding

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • People with a past severe allergic reaction to degarelix or any product component

Interactions

  • Drugs that prolong the QT interval: androgen deprivation can also prolong QT, adding heart rhythm risk

Serious risks

  • Severe allergic reactions, including anaphylaxis and angioedema
  • QT prolongation (a heart rhythm change), especially with long QT syndrome, heart failure or electrolyte problems
  • Fetal harm and pregnancy loss, based on animal studies
  • Can alter results of hormone-related lab tests

Common side effects

  • injection-site pain, redness or swelling
  • hot flashes
  • raised liver enzymes

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Firmagon (degarelix) prescribing information ↗

What the featured evidence can tell us

Current medicine information should guide precautions and monitoring. PRONOUNCE does not establish that either approach has no cardiovascular risk.

Source: NCI · Degarelix ↗

Identity, route, and evidence limits

Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.

Source: Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. · 2021 ↗

Regulatory status

U.S. FDA approval
Approved
Firmagon (NDA 022201, approved December 2008) for advanced prostate cancer. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named. S2.2.1 covers GnRH agonist analogues; degarelix is a GnRH antagonist. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Medicine status & clinical context

NCI identifies degarelix, marketed as Firmagon, as FDA-approved for advanced prostate cancer. The PRONOUNCE study examines cardiovascular outcomes within that treatment setting; it does not establish a general longevity or cardiovascular-prevention indication.

NCI identifies degarelix as a prostate-cancer treatment. The featured trial addresses a narrower cardiovascular-safety comparison in people with established atherosclerotic cardiovascular disease.

Source: NCI · Degarelix and FDA-approved cancer use ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

How Degarelix works

GnRH receptor antagonism suppresses the reproductive-hormone pathway through a different receptor approach from GnRH agonists. A mechanistic difference does not itself prove cardiovascular superiority.

Source: Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. · 2021 ↗

Molecular structure

Degarelix: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 16136245 ↗

Questions worth asking

  • Did PRONOUNCE prove better cardiovascular safety?
  • What population, comparator, and route were actually studied?
  • Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Did PRONOUNCE prove better cardiovascular safety?

No. The trial stopped early and the event comparison was not statistically significant; the comparative question remained unresolved.

Source: Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. · 2021 ↗

Does this page establish a supplier’s product quality?

No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.

Source: Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. · 2021 ↗

Does the official medicine reference cover every use discussed online?

No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.

Source: NCI · Degarelix and FDA-approved cancer use ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Degarelix

Download illustration ↓Source record ↗
Degarelix 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.